{"entity":{"id":"nct05684965","kind":"trial","name":"XTX301 in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of XTX301 in advanced solid tumours, run by Xilio Development, Inc., now recruiting.","summary":"XTX301 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05684965 by Xilio Development, Inc., with 358 participants planned, started 2023-05-11 and due to reach its primary completion in 2028-09. Interventions recorded: XTX301.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05684965","url":"https://clinicaltrials.gov/study/NCT05684965"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["xilio-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05684965","phase":"1/2","setting":"A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX301 in Patients With Advanced Solid Tumors","sponsor":"Xilio Development, Inc.","participation":[{"nct":"NCT05684965","source":"https://clinicaltrials.gov/study/NCT05684965","fetchedAt":"2026-10-07T16:53:49.617Z","studySha256":"d0b775c2c4e6ef3e6559fb4a54abd249463ba78153f02947965dc6d3ea5a7ef6","overallStatus":"RECRUITING","lastUpdatePosted":"2026-06-23","leadSponsor":"Xilio Development, Inc.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":358,"enrolmentType":"ESTIMATED","siteCount":12,"recruitingSiteCount":10,"countries":["United States"]}],"started":"2023-05-11","startedType":"actual","enrolled":358,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05684965/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"xilio-therapeutics","kind":"company","name":"Xilio Therapeutics","route":"/companies/xilio-therapeutics/"}]}}